Introduction {#s1}
============

After the first cases of swine-origin influenza A were described in Mexico and the United States in April 2009, pandemic influenza A (H1N1) 2009 spread throughout the world. [@pone.0084121-Dawood1], [@pone.0084121-World1] The first case of pandemic (H1N1) 2009 in the Republic of Korea (ROK) was identified in a person returning from Mexico on May 2, 2009, and virus activity subsequently increased rapidly. [@pone.0084121-Lee1]--[@pone.0084121-KCDC1].

Because of the high rates of incidence, the medical costs of pandemic (H1N1) 2009 have been considerable. [@pone.0084121-Bautista1]--[@pone.0084121-Lee3] In order to prevent the spread of pandemic (H1N1) 2009, the government was not performed only the health policy, such as quarantine, isolation, and campaign for hygiene, but also the government was responsible for stockpiling antivirals and developing and producing vaccines. [@pone.0084121-Lee1], [@pone.0084121-Lee4] Pandemic (H1N1) 2009 would become a significant burden in both healthcare and socioeconomic system.

On the other hands, the government was conducted surveillance system for investment the scale occurred influenza. However, the surveillance may have been under-reporting, because the surveillance was included serological confirmed patients. Therefore, efforts are needed to estimate the exact socioeconomic burden of pandemic (H1N1) 2009.

Although several studies have been conducted to estimate disease the burden or medical costs of pandemic (H1N1) 2009, these studies focused on disease severity, effective vaccination, or community mitigation strategies. [@pone.0084121-vanHoek1]--[@pone.0084121-Homaira1] Due to limitations of representative national statistics, estimation on economic impact of pandemic (H1N1) 2009 has not been conducted.

The purpose of this study was to determine the socioeconomic burden of seasonal influenza (2007--2008 \[May 2007 to April 2008\] and 2008--2009 seasons \[May 2008 to April 2009\]) and pandemic (H1N1) 2009 (2009--2010 influenza season \[May 2009 to April 2010\]) in the ROK and to compare medical costs and socioeconomic burden of pandemic (H1N1) 2009 with those of seasonal influenza.

Methods {#s2}
=======

Data Sources {#s2a}
------------

### Medical Care Utilization Data {#s2a1}

Medical care utilization data (e.g., date clinic/hospital visit, medical service, and cost per service) were obtained from the Health Insurance Review & Assessment Service (HIRA). ([Table 1](#pone-0084121-t001){ref-type="table"}) All legal residents of the ROK are covered by the National Health Insurance program, which uses a fee-for-service payment system to reimburse healthcare providers. [@pone.0084121-Kim2] The Korean government regulates these fees, and HIRA has the authority to review healthcare insurance claims and assess healthcare quality. We selected all insurance claims in which influenza was diagnosed (International Classification of Diseases, 10th Revision, Clinical Modification \[ICD-10-CM\] codes: J09--J11) between May 2007 and April 2010.

10.1371/journal.pone.0084121.t001

###### Parameter and data sources.

![](pone.0084121.t001){#pone-0084121-t001-1}

                                                                                 parameter                                                       Distribution of assumption factors[\*](#nt101){ref-type="table-fn"}                                 Data source     
  ---------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------
  **Direct costs**                                                                                                                                                                                                                                                   
  Direct medical costs                                                                                                                                                                                                                                               
   Medical costs of inpatient and outpatient                                Total medical cost                                                                                                                                                        HIRA data             HIRA data
   Stockpile antivirals                                                   Total cost of antiviral                                                                                                                                                        \-                 NHIC data
  Direct non-medical costs                                                                                                                                                                                                                                           
   Transport costs of inpatient                                        Number of visits to inpatient                                                                                                                                                  HIRA data             HIRA data
                                                                                Return fare                                                                       Normal (Mean  = 19.2, SD = 1.92)                                                     KNHNES                 KNHNES
   Transport costs of outpatient                                      Number of visits to outpatient                                                                                                                                                  HIRA data             HIRA data
                                                                                Return fare                                                                       Normal (Mean  = 15.5, SD = 1.55)                                                     KNHNES                 KNHNES
  **Indirect costs**                                                                                                                                                                                                                                                 
  Productivity losses due to morbidity of inpatient     Number of visits to inpatient & Duration of hospitalization                                                                                                                                   HIRA data             HIRA data
                                                           Average daily earnings & Employment-population ratio                                                                                                                                      KOSIS data             KOSIS data
  Productivity losses due to morbidity of outpatient                  Number of visits to outpatient                                                                                                                                                  HIRA data             HIRA data
                                                                          Duration of sick leave                      Seasonal influenza: Uniform (Range: 0.5--4.5); H1N1 Influenza 2009: Negative binomial (Probability  = 0.7166, Shape  = 5)   Literature review       Mailing survey
                                                           Average daily earnings & Employment-population ratio                                                                                                                                      KOSIS data             KOSIS data
  Productivity losses of caregiver                                        Duration of sick leave                      Seasonal influenza: Uniform (Range: 0.5--4.5); H1N1 Influenza 2009: Negative binomial (Probability  = 0.7166, Shape  = 5)   Literature review       Mailing survey
                                                        Female average daily earnings & Employment-population ratio                                                                                                                                  KOSIS data             KOSIS data
  Productivity losses due to premature mortality                              Mortality data                                                                                                                                                         KOSIS data       KCDC surveillance data
                                                                 Life expectancy & Average annual earnings                                                                                                                                           KOSIS data             KOSIS data
  **Prevention strategy**                                                                                                                                                                                                                                            
  Execution of the budget                                 Execution of the budget regarding pandemic (H1N1) 2009                                                                                                                                         \-                    KNAB
  Protective equipment                                                 Price of prevention equipment                                                                 Uniform (Range: 0.47--4.7)                                                          \-             Literature review
                                                                         Probability of purchasing                                                                Normal (Mean  = 0.325, SD = 0.03)                                                      \-             Literature review

\*Uncertainty of the data was explored through probabilistic sensitivity analysis using Monte Carlo simulation.

### Monitoring of stockpiled antivirals {#s2a2}

Before 2009--2010 season, because few antivirals for influenza were on the market in the ROK due to rare prescriptions, almost all antivirals for pandemic (H1N1) 2009 were stockpiled and managed by the government in 2009--2010 season. Since August 21, 2009, the Korea Centers for Disease Control and Prevention (KCDC) and National Health Insurance Corporation have monitored daily prescription of antivirals for influenza. [@pone.0084121-Kim1].

### Mortality Data {#s2a3}

Death certificate data from the Korean Statistical Information Service (KOSIS) were used to determine influenza mortality (ICD-10-CM: J09--J11) for seasonal influenza during 2007--2009. [@pone.0084121-Korean1] The KCDC began active surveillance of pandemic (H1N1) 2009-related mortality from August 15, 2009 (date of the first fatality), and a fatal case was defined as a person with pandemic (H1N1) 2009, confirmed by ante-mortem or post-mortem specimens, who died from a clinically compatible illness or complications attributable to that infection. In 2009--2010 season, we used surveillance data from KCDC from August 15, 2009 until April 30, 2010.

Estimating Cost of Illness {#s2b}
--------------------------

The socioeconomic burden of influenza was estimated as direct costs, indirect costs, and costs associated with prevention strategies. To compare the socioeconomic burden of seasonal influenza in the 2007--2008 and 2008--2009 seasons with that of pandemic (H1N1) 2009, all resource utilization estimates were obtained for 2009 and expressed in 2009 United States dollars (US\$) using the 2009 average exchange rate (US\$1 = 1276.4 Korean won; Bank of Korea).

### Direct Costs {#s2b1}

Direct healthcare costs consisted of medical services and medication. Total medical costs associated with influenza(ICD-10-CM codes: J09--J11) were obtained by adding costs reported by all clinics and hospitals to HIRA for each season. Non-stockpile antivirals and other drug costs were included in medication costs reported by HIRA. Because stockpiled antivirals were provided for free only in the 2009--2010 season, cost of stockpiled antivirals was estimated as the cost of each drug multiplied by the total number of prescriptions.

Direct non-healthcare costs consisted of transport costs related to clinic or hospital visits. Transport costs were estimated by multiplying the total number of clinic visits by the return fare, reported by the 2005 Korean National Health and Nutrition Examination Survey. [@pone.0084121-Korea1] To estimate the cost of return fares, the healthcare component of the Korean Consumer Price Index was used to adjust costs to the 2009 values.

### Indirect Costs {#s2b2}

Indirect costs resulting from productivity losses were estimated as: 1) productivity losses due to morbidity, 2) productivity losses of caregiver, and 3) premature mortality resulting from influenza. Indirect costs were estimated using a human capital approach by multiplying expected mean earnings by time lost at work and adjusted by the employment-population ratio by matching gender and age.

Productivity losses of adults (20--64 years old) were estimated from the average earnings in the general population (adjusted by the employment--population ratio) by matching gender and age. [@pone.0084121-Korean1] For inpatients, we multiplied average daily earnings by hospitalization day. For outpatients, we multiplied average daily earnings by sick leave duration based on the first outpatient visit. Subsequent outpatient visits were assumed to be follow-up appointments for influenza, and work loss was estimated as a half day. For calculating the outpatients productivity losses, sick leave of outpatients (range: 0.5--4.5 days) was assumed according previously published data for the 2007--2008 and 2008--2009 seasons. [@pone.0084121-Keech1], [@pone.0084121-Galante1] For the 2009--2010 season, we surveyed patients with laboratory-confirmed pandemic (H1N1) 2009 between August 2009 and February 2010 in four university-based quarantine hospitals (representing four provinces in the ROK). The survey asked, "How many days of sick leave did you take to stay home with influenza?" We mailed questionnaires to 10,833 patients in February and May 2010, and 2,166 patients (20.0%) responded. Median sick leave of patients was 7 days (range: 1--28).

Unless they were admitted to the hospital, we assumed that children ≤19 years and adults ≥65 years required care from a family member, and that most caregivers were women. Caregiver productivity losses were calculated by multiplying the time required to care for a sick family member by average daily earnings.

Lost earnings due to premature mortality were calculated from the number of influenza-related deaths and the annual earnings of those patients. Only patients \<65 years old (standard retirement age) were included in this analysis. The expected future loss of earnings due to premature mortality was adjusted using a 5% discount rate. Life expectancy, average annual earnings, and employment--population ratio by age and gender were based on 2009 general population data from the KOSIS. [@pone.0084121-Korean1].

### Prevention Strategy {#s2b3}

Costs associated with prevention strategies (national budget for influenza prevention and use of protective equipment) were estimated only for the 2009--2010 season, because complete data were not available for the other seasons. Data for execution of the budget regarding pandemic (H1N1) 2009 (quarantine facilities, vaccine development, vaccine/antiviral stockpiles) were obtained from the Korean National Assembly Budget office. [@pone.0084121-Korean2] Direct costs consisted of the cost of stockpiled antivirals based on the actual usage; costs associated with used stockpiled antivirals were excluded for estimating of the costs associated with prevention strategies. The cost of protective equipment (e.g., masks, hand sanitizers) was calculated by multiplying purchase price by the probability of purchasing (estimated as 32.5%), based on a survey. [@pone.0084121-Samsung1] Direct and indirect influenza-related costs were based on the target population (patients), however prevention costs were based on the entire population.

Statistical Analysis {#s2c}
--------------------

Total costs were defined as the sum of direct costs, indirect costs, and costs associated with prevention strategies. Data were compared by chi-square test or one-way analysis of variance to determine differences in medical costs across seasons. While available national data such as medical costs and cost of antiviral was used as fixed values, some data such as transport costs and duration of sick leave, used as assumed value. Therefore, uncertainty of the assumed data was explored through probabilistic sensitivity analysis (1,000 independent simulation trials) using Monte Carlo simulation (Oracle Crystal Ball, version 11.1.1.30, Oracle Corporation). the Monte Carlo simulation assumed normal distribution for transport costs (mean ± standard deviation; inpatients: 19.16±1.916, outpatients: 15.47±1.547), uniform distribution of sick leave days for seasonal influenza (range: 0.5--4.5) in 2007--2008 and 2008--2009 seasons, and negative binomial distribution for sick leave associated with pandemic (H1N1) 2009 (probability  = 0.7166, shape  = 5), which was fitted to questionnaire data. (see [Table 1](#pone-0084121-t001){ref-type="table"} for more details on parameters and distribution of assumption factor).

Ethics Statement {#s2d}
----------------

This study was approved by the institutional review board of Yonsei University Health System (approval number: 4-2011-0279).

Results {#s3}
=======

During the 2009--2010 season (week 17, 2009 through week 16, 2010), a total of 266 fatal cases were reported ([Figure 1](#pone-0084121-g001){ref-type="fig"}). Outpatient visits and antiviral prescriptions peaked at week 43. Vaccinations against pandemic (H1N1) 2009 began on October 27, 2009, when the number of outpatient visits peaked (746,290/week).

![Outbreak of Pandemic Influenza A (H1N1) 2009 and Main Response Strategy in Korea.](pone.0084121.g001){#pone-0084121-g001}

Inpatient visits during the 2009--2010 season (123,035) increased 15- to 20-fold compared with two previous seasons, and outpatient visits (4,609,026) increased 10-fold ([Table 2](#pone-0084121-t002){ref-type="table"}). The number of visits per person during the 2009--2010 season was not increased compared with two previous seasons. During the 2009--2010 season, total medical costs of inpatients increased 20-fold and those costs of outpatients increased 50-fold. In both inpatient and outpatient, the medical costs of all subcategory during the 2009--2010 season increased compared with two previous seasons. The proportion of each subcategory among inpatient medical costs was not different among seasons (P-value  = 0.598); whereas, the proportion of each subcategory among outpatient differed significantly (P-value \<0.001). The mean cost per visit differed significantly across seasons for both inpatients and outpatients. Among the subcategory of medical cost, the mean diagnostic cost per visit in the 2009--2010 season was significantly increased compared with two previous seasons.

10.1371/journal.pone.0084121.t002

###### Number of Visits and Medical Costs for Influenza in the Republic of Korea, 2007--2010.
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                                                                      2007--2008 Season   2008--2009 Season   2009--2010 Season   P-value[\*](#nt102){ref-type="table-fn"}                        
  ------------------------------------------------------------------ ------------------- ------------------- ------------------- ------------------------------------------ ----------- --------- ---------
  **Total number of visits**                                                                                                                                                                      
  Inpatients                                                                6,502               8,775              123,035                                                                        
  Outpatients                                                              446,713             404,623            4,609,026                                                                       
  **Number of visits per person** [†](#nt103){ref-type="table-fn"}                                                                                                                                
  Inpatients                                                              1.07±0.28           1.05±0.22           1.06±0.25                                                                       
  Outpatients                                                             1.84±2.26           1.75±2.10           1.45±1.07                                                                       
  **Medical costs** (thousand US\$)                                                                                                                                                               
  Inpatients                                                                                                                                                                                      
   Total costs                                                             2,740.4             (100.0)             3,799.3                        (100.0)                    77,004.9    (100.0)  
   Consultation costs                                                      1,358.0             (49.6)              1,924.8                         (50.7)                    34,359.8    (44.6)     0.598
   Diagnostic costs                                                         513.1              (18.7)               717.2                          (18.9)                    20,872.1    (27.1)   
   Medication and other costs                                               869.2              (31.7)              1,157.4                         (30.5)                    21,773.0    (28.3)   
  Outpatients                                                                                                                                                                                     
   Total costs                                                             4,428.9             (100.0)             4,102.7                        (100.0)                    214,649.0   (100.0)  
   Consultation costs                                                      3,897.4             (88.0)              3,544.2                         (86.4)                    55,542.1    (25.9)    \<0.001
   Diagnostic costs                                                         175.0               (4.0)               205.0                          (5.0)                     135,313.9   (63.0)   
   Medication and other costs                                               356.6               (8.1)               353.5                          (8.6)                      23793.0    (11.1)   
  **Costs per visit** (US\$)[†](#nt103){ref-type="table-fn"}                                                                                                                                      
  Inpatients                                                                                                                                                                                      
   Total costs                                                          421.4±422.75        432.9±411.83        625.8±800.81                      \<0.001                                         
   Consultation costs                                                   208.8±213.38        219.3±190.71        279.2±356.30                      \<0.001                                         
   Diagnostic costs                                                      78.9±105.86         81.7±103.78        169.6±190.50                      \<0.001                                         
   Medication and other costs                                           133.7±145.33        131.9±173.53        176.9±347.68                      \<0.001                                         
  Outpatients                                                                                                                                                                                     
   Total costs                                                            9.9±7.53            10.1±9.10          16.6±56.32                       \<0.001                                         
   Consultation costs                                                     8.7±4.16            8.8±3.74            12.0±9.54                       \<0.001                                         
   Diagnostic costs                                                       0.4±3.65            0.5±5.32           29.4±41.64                       \<0.001                                         
   Medication and other costs                                             0.8±2.35            0.9±3.37            5.2±21.17                       \<0.001                                         

\*P-values for proportional difference of subcategories of medical costs across seasons were determined by chi-square tests, and P-values for mean difference of costs per visit across seasons were determined by analysis of variance.

Results are expressed as mean ± standard deviation.

We estimated the socioeconomic costs of influenza consisted of direct costs (direct medical and non-medical costs), indirect costs (productivity losses of morbidity, caregiver, and premature mortality), and costs associated with prevention strategies (execution of the budget and protective equipment) ([Table 3](#pone-0084121-t003){ref-type="table"}). We varied the return fare for outpatients and inpatients, the duration of sick leave, and the probability of purchasing and the price of preventative equipment. Based on results of the Monte Carlo simulation, the socioeconomic burden for pandemic (H1N1) 2009 was estimated at US\$1,581.3 million, and those of seasonal influenza were US\$44.7 million in 2007--2008 season and US\$42.3 million in 2008--2009 season. Indirect costs were the largest proportion of total costs. In 2009--2010 season, 56.0% of total costs were indirect costs, consisting primarily of productivity losses of caregivers (30.0%) and morbidity (outpatient: 24.3%, inpatient 0.62%). In 2007--2008 and 2008--2009 seasons, the cost of productivity losses due to morbidity was the largest component.

10.1371/journal.pone.0084121.t003

###### Estimating Costs of Illness for Pandemic Influenza A (H1N1) 2009 and Seasonal Influenza in the Republic of Korea, 2007--2010.
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                                                         2007--2008 Season     2008--2009 Season    2009--2010 Season                                           
  ---------------------------------------------------- ---------------------- ------------------- ---------------------- -------- ----------------------------- --------
  **Direct costs**                                                                                                                                              
  Direct medical costs                                                                                                                                          
   Medical costs of inpatients                                  2.74                 6.16                  3.80            8.90               77.00               4.79
   Medical costs of outpatients                                 4.43                 9.95                  4.10            9.61              214.61              13.37
   Stockpile antivirals                                          NA                   NA                    NA              NA                41.46               2.58
  Direct non-medical costs                                                                                                                                      
   Transport costs of inpatients                         0.12 (0.11--0.14)           0.28            0.17(0.15--0.19)      0.39         2.35 (2.04--2.65)         0.15
   Transport costs of outpatients                        6.91 (5.98--7.84)           15.53          6.23 (5.50--7.01)     14.61       71.16 (61.77--80.78)        4.43
  **Indirect costs (Productivity losses)**                                                                                                                      
  Productivity losses due to morbidity of inpatient             0.60                 1.35                  0.62            1.46               9.93                0.62
  Productivity losses due to morbidity of outpatient     20.10(8.99--32.58)          45.16          18.31(7.86--28.98)    42.92      390.23 (281.16--499.30)     24.30
  Productivity losses of caregiver                       9.54(4.38--14.42)           21.43          9.32(4.22--14.52)     21.84      480.00(347.75--612.25)      29.89
  Productivity losses due to premature mortality                0.07                 0.15                  0.11            0.26               19.16               1.19
  **Prevention strategy**                                                                                                                                       
  Execution of the budget                                        NA                   NA                    NA              NA               259.26              16.15
  Protective equipment                                           NA                   NA                    NA              NA        40.60 (14.50--68.85)        2.53
  **Total socioeconomic costs**                         44.65 (32.35--57.87)        100.00         42.31 (31.50--53.75)   100.00   1,581.27 (1435.96--1808.33)   100.00

NA: not available Costs are expressed as fixed value or median value (range, 10%--90%).

Discussion {#s4}
==========

Inpatient visits, outpatient visits, and total medical costs increased significantly in the 2009--2010 season compared to two previous seasons in the ROK. The 2009--2010 medical costs (US\$291.7 million) accounted for 1.24% of the 2009 total national healthcare expenditures (US\$23.48 billion). In contrast, 2007--2008 medical costs (US\$7.17 million) accounted for only 0.04% of 2007 national healthcare expenditures (US\$19.25 billion), and 2008--2009 medical costs (US\$7.90 million) were about 0.04% of 2008 national healthcare expenditures (US\$20.67 billion). These findings demonstrate the significance of pandemic (H1N1) 2009 as a major public health concern in the ROK. [@pone.0084121-National1].

Compared with the 2007--2008 season, outpatient diagnostic costs were 773 times higher in the 2009--2010 season, and the mean diagnostic cost per outpatient visit was 58.8 times higher. In addition to the increased number of influenza cases, the higher medical costs during the 2009--2010 season may be due to the increased use of diagnostic tests including real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Although laboratory tests can confirm influenza cases, clinical judgment by physicians is important in the identification of influenza. On October 30 (week 43) 2009, the government recommended antivirals administration who met the case definition of influenza-like illness, without laboratory confirmation. However, diagnostic costs did not decrease after that time.

Besides public fears about the pandemic, other factors may be associated with the increased diagnostic testing. First, in the ROK, medical cost consist those covered by insurer and those covered by patients (coinsurance) due to the National Health Insurance program. Before March 2010, the National Health Insurance program covered 40--50% of the cost for RT-PCR testing, suggesting overutilization of these tests because they were relatively inexpensive for the patient. After March 2010(week 11), the patient covered up to 100% of real-time RT-PCR costs, decreasing its proportion of diagnostic costs. Second, most schools and workplaces required negative diagnostic test results for suspected cases during the pandemic, despite government recommendations. Therefore, suspected cases visited clinics and were examined laboratory tests to obtain a medical certificate and not to get treatment. The medical cost breakdown did not differ significantly among age groups, suggesting that age groups not incurred greater diagnostic costs (data not shown).

In this study, total 2009--2010 socioeconomic costs (US\$1,581.3 million) accounted for 0.19% of the 2009 gross domestic product (US\$832.9 billion). In contrast, total 2007--2008 socioeconomic costs (US\$44.7 million) accounted for only 0.005% of the 2008 gross domestic product. In the 2007--2008 and 2008--2009 seasons, indirect costs were the largest proportion of total costs. Specifically, 56.0% of 2009--2010 costs were indirect costs, consisting primarily of productivity losses of caregivers (30.0%) and adult outpatients (24.3%). In the pandemic\'s early stage, public health officials recommended that students and employees with influenza rest at home for a week, whereas the mean sick leave was \<1 to 4.3 days for typical seasonal influenza. [@pone.0084121-Keech1], [@pone.0084121-Mota1] This longer sick leave may have contributed to the high indirect costs for pandemic (H1N1) 2009.

The ROK has several national surveillance systems including pneumonia and influenza surveillance and sentinel surveillance for influenza-like illness known as the Korea Influenza Surveillance Scheme. [@pone.0084121-Lee3] However, the ROK does not have a hospital-based surveillance system for emerging diseases, such as the Emerging Infections Program in the United States, which collects data about susceptibility, clinical course, treatment efficacy, and outcomes. [@pone.0084121-Creanga1] Therefore, little information on these data was available in the early stages of the pandemic in the ROK. Although the severity of pandemic (H1N1) 2009 was similar to that of typical seasonal influenza, early response strategies in the ROK (e.g., confirmation testing, social distancing) were not effectively changed because of limited national data regarding clinical characteristics.

Our study has some limitations. First, we could not include costs incurred by asymptomatic patients or those not admitted to the hospital in calculating influenza-related costs. We considered preventative actions taken by the general population and execution of the budget (including an improved response system) and its promotion to the general population. Second, the rapid antigen test for influenza was also widely used in the ROK. However, the National Health Insurance Corporation did not cover this test; therefore, we could not acquire data regarding its use or include these costs in our analysis. Third, we estimated outpatient sick leave based on the first clinic visit only and assumed no recurrence or infection with other influenza strains. Therefore, the diagnostic and productivity costs may also be underestimated. In addition, misclassification and underreporting may affect our study. When pneumonia occurs as a complication of influenza, influenza cases may be coded as pneumonia (ICD-10-CM codes: J12--J18). However, misclassification or underreporting of influenza may have been lower in the 2009--2010 season (when confirmation tests were widely used), resulting in overestimated differences in medical costs. We found that the number of pneumonia cases and fatal cases in the 2009--2010 season were similar to numbers reported in previous seasons ([Table S1](#pone.0084121.s001){ref-type="supplementary-material"}). Therefore, misclassification did not appear to have affected our results. Mortality data were obtained from death certificates for the 2007--2008 and 2008--2009 seasons. When several disease codes can be used as cause of death, the most severe disease is generally used on a death certificate. Therefore, influenza mortality may be misclassified/underreported, underestimating the costs of premature mortality. Because in 2009--2010 season the KCDC mortality surveillance data was used, the costs of premature mortality of 2009--2010 season could not compare with those of previous season.

Because of this potential underestimation in influenza-associated costs, the true socioeconomic burden of pandemic (H1N1) 2009 may exceed our estimate. Although a conservative formula was used, we found that total costs and average costs per visit of pandemic (H1N1) 2009 were significantly higher than those of typical seasonal influenza.

In conclusion, medical and socioeconomic costs of pandemic (H1N1) 2009 were considerably higher than costs of the previous two influenza seasons, primarily because of longer sick leave and high diagnostic costs. Therefore, government policies such as risk communication concerning sick leave and diagnostic testing could be modified to reduce the socioeconomic burden in similar situations. In addition, a surveillance system for clinical characteristics (e.g., susceptibility, treatment efficacy, adverse drug reactions, and severity) in the early stages of an outbreak is needed.
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